Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 29 October 2026.

Announcements

660

Total raised

£938M

disclosed amounts

This month

£15.9M

raised so far

Pre-Seed
£8.2M

The round was backed by Inflection, Final Frontier, and other investors to scale ground station construction and hardware manufacturing.

"Every time you tap your card, check your map or make a phone call, you’re relying on satellite infrastructure — but the technology we use to track exactly where satellites are hasn’t kept up with the explosion of the space economy."
— Hira Virdee, CEO and co-founder
Pre-Seed
£850K

The round was led by Haatch, with participation from Setanta Vehicle Importers and Fhunded Angels.

"This significant funding round will help us get to the next stage of our development; enabling us to expand our team, strengthen our technology, and accelerate our work with vehicle operators, energy partners, and industry stakeholders."
— Will Maden
Pre-Seed
£1.5M

The round was backed by a syndicate of investors including Aligned Syndicate, Leeds Angels, and Arx Ventures.

"At the moment, models can’t verify themselves. So when a bank, for example, ships machine-written code into production, that’s on the model’s word that it’s safe."
— Patrick Rycroft, Co-founder and CEO
Pre-Seed
€5.0M

The financing round was led by firstminute capital and Global Founders Capital.

"Audit is one of the few services where the customer experience has got worse every year while the bill has gone up. We are not changing what an audit is. We are changing how it is delivered."
— Thibault Mallion, Co-founder and Co-CEO
Pre-Seed
£1.5M

The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures and will support the transition of designed drug combinations into wet-lab validation.

"Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab."
— Kerstin Papenfuss, CEO and co-founder